LIGAND PHARMACEUTICALS INC - 01 Nov 2022 Form 4 Insider Report for OmniAb Operations, Inc.

Role: 10%+ Owner
Signature: /s/ Andrew Reardon, Chief Legal Officer and Secretary of Ligand Pharmaceuticals Incorporated
Issuer symbol: N/A
Transactions as of: 01 Nov 2022
Net transactions value: $0
Form type: 4
Filing time: 03 Nov 2022, 21:12:13 UTC
Previous filing: 30 Sep 2022
Next filing: 03 Jul 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction		Common Stock	Other	$0	-16,859,308	-100%	$0.000000^*	0	01 Nov 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

LIGAND PHARMACEUTICALS INC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	In connection with the separation of the Issuer from the Reporting Person on November 1, 2022, the Reporting Person distributed all of the shares of Common Stock of the Issuer in the form of a dividend to its stockholders.